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Triantafillos Liloglou15, Lambertus A. Kiemeney16, Philip Lazarus17, Bernadette Wendel1, Aage Haugen18,
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Susanne M. Arnold23, Gary E. Goodman24, Chu Chen25, Jennifer A. Doherty26, Fiona Taylor27, Angela Cox27,
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Abstract
Background: Aberrant Wnt signalling, regulating cell development and stemness, influences the development
of many cancer types. The Aryl hydrocarbon receptor (AhR) mediates tumorigenesis of environmental pollutants.
Complex interaction patterns of genes assigned to AhR/Wnt-signalling were recently associated with lung cancer
susceptibility.
Aim: To assess the association and predictive ability of AhR/Wnt-genes with lung cancer in cases and controls of
European descent.
Methods: Odds ratios (OR) were estimated for genomic variants assigned to the Wnt agonist and the antagonis‑
tic genes DKK2, DKK3, DKK4, FRZB, SFRP4 and Axin2. Logistic regression models with variable selection were trained,
validated and tested to predict lung cancer, at which other previously identified SNPs that have been robustly associ‑
ated with lung cancer risk could also enter the model. Furthermore, decision trees were created to investigate vari‑
ant × variant interaction. All analyses were performed for overall lung cancer and for subgroups.
Results: No genome-wide significant association of AhR/Wnt-genes with overall lung cancer was observed, but
within the subgroups of ever smokers (e.g., maker rs2722278 SFRP4; OR = 1.20; 95% CI 1.13–1.27; p = 5.6 × 10–10) and
never smokers (e.g., maker rs1133683 Axin2; OR = 1.27; 95% CI 1.19–1.35; p = 1.0 × 10–12). Although predictability is
poor, AhR/Wnt-variants are unexpectedly overrepresented in optimized prediction scores for overall lung cancer and
for small cell lung cancer. Remarkably, the score for never-smokers contained solely two AhR/Wnt-variants. The opti‑
mal decision tree for never smokers consists of 7 AhR/Wnt-variants and only two lung cancer variants.
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Conclusions: The role of variants belonging to Wnt/AhR-pathways in lung cancer susceptibility may be underrated
in main-effects association analysis. Complex interaction patterns in individuals of European descent have moderate
predictive capacity for lung cancer or subgroups thereof, especially in never smokers.
Keywords: Susceptibility, Association, Gene–gene integration, Prediction, Polygenic risk score, Decision trees, Never
smoker, Small cell lung cancer

Background
Lung cancer (LC) is the most common cancer worldwide
since 1985. It is the leading cause of cancer related death
around the world [1]. It was estimated for 2020, that globally 2.2 million new LC-cases were diagnosed, which are
11.4% of all new cancer cases. In the same year 1.8 million LC-cases died, which are 18% of all cancer related
deaths [2]. The lifetime risk of developing a clinical manifest lung cancer (from birth to age 74) is higher in men
(3.78%) than in women (1.77%).
The Wnt signalling pathway is a multi-regulator of, e.g.,
cell proliferation, differentiation, genetic stability, and
much more. It is crucial in the development of embryos
and in the dynamic balance of adult tissues, so also that
of the lung. With respect to LC, changes of the Wnt signalling pathway have been observed for Wnt ligands,
frizzled, TCF/LEF (T cell factor/lymphoid enhancer
factor)-dependent transcription, and Wnt inhibitor
silencing [3].
Genome-wide association studies (GWAS) have
identified dozens of susceptibility loci throughout the
genome that are associated with the susceptibility to
lung cancer or one of its histological subtypes [4–11].
Genes related to Wnt signalling, one of the key pathway regulating cell development and stemness, were
not detected as being associated to LC susceptibility
in individuals of European descent so far, unlike TERT
(5p15.33) that was one of the first for which a robust
association was observed [12]. Aberrant Wnt signalling
is often observed in expression profiles of many cancers, but to date no association of Wnt/Ahr genes with
susceptibility to cancer of any type has been observed
[13–15]. Administration of RNAi against Wnt was
shown to reduce tumour burden in lung adenocarcinoma (adenoLC) [16]. In non-small cell lung cancer (NSCLC), overexpressed miR-582-3p maintains
stemness features by negatively targeting the regulators of Wnt signalling Axin2, DKK3 and SRP1 for degradation, thereby increasing β-catenin mediated Wnt
activity [17]. TERT expression was found to be directly
enhanced by binding of β-catenin to its promoter
region and thereby links telomerase activity to Wnt
signalling [13]. This is as much important, as TERT is
one of the first and most robust susceptibility genes for
LC identified by GWAS [18, 19]. The tight regulatory

machinery of the Wnt pathway has several major antagonists, such as Secreted Frizzled related protein (sFRP),
Dickopff 5 (DKK) protein and Axin2 protein [20]. Evidence also exists for a crosstalk between AhR and Wnt
signalling [21].
Aryl hydrocarbon receptor (7p21.1; AhR) is a ligand
induced transcription factor, which is translocated into
the nucleus. It is known to mediate the toxicity and
tumorigenesis of a variety of environmental pollutants,
including for NSCLC. AhR upregulates the enzyme
CYP1A1 when cells are exposed to carcinogenic metabolites, such as some polycyclic aromatic hydrocarbons
(PAHs) found in cigarette smoke. The CYP1A1 coding
gene is discussed as a susceptibility gene for LC. AhR is
a major determinant in the process of smoking driven
LC [22–24]. The complexity of both the AhR signalling
pathway and the Wnt signalling cascade is reflected by
interaction effects of genomic variants within genes,
which control their function [25]. Recently, the association of the Wnt-genes DKK4 (8p11.21), DKK3
(11p15.3), DKK2 (4q25), FRZB (2q32.1, also known as
sFRP3), SFRP4 (7p14.1), Axin2 (17q24.1) and a potential interaction with AhR was investigated with respect
to the susceptibility to LC in a sample of 600 subjects
from North India [25, 26]. A notable association with
LC, e.g., for the SFRP4 variant rs1802073 (OR = 3.19;
95% CI 1.81–5.63), was reported. Classification And
Regression Tree (CART) analysis revealed an interaction of DKK2 and SFRP4 polymorphisms to be the best
(off all investigated) predictors for LC; especially within
smokers. They also reported to have identified several
high-risk subgroups in smokers, e.g., characterised by
DKK2 (rs17037102/rs419558) and Axin2 (rs9915936).
A similar picture was observed in a sample of 270 subjects from Istanbul, Turkey [27]. A two-way interaction
between DKK3 (rs3206824) and SFRP4 (rs1802074) was
found to be predictive of LC.
We aimed to assess a possible association of AhR pathway and Wnt signalling cascade with LC within the largescale series of cases and controls of European descent
hold by the International Lung Cancer Consortium
(ILCCO)/Integrative analysis of Lung Cancer Etiology
and Risk (INTEGRAL). To do this, we also evaluated the
contribution of these genes to genetic prediction of LC as
a complement to known LC-related markers.
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Methods
The work presented has been reviewed and approved
by the ILCCO Steering Committee.
Cases and controls

Phenotype and genotype data of 58,181 entries of the
data repository of ILCCO were extracted. Details of the
repository is described previously [4, 28]. QC control
samples, individuals without information on smoking status or age, and samples of poor genotyping
quality or sex discrepancies, were excluded. To avoid
population stratification, this analysis is focused on
European-ancestry population (defined as more than
95% probability of being of European descent). Fourteen thousand sixty-eight incident LC-cases and 12,390
cancer-free controls of European descent remained for
analysis. Those genotyped with other genome-wide
array in addition to OncoArray were separated to form
an independent validation set (2nd validation set) of
size (n = 4359, including 2360 LC-cases and 1999
controls).
Selected markers

For this investigation we extracted the genotypes of
113 genomic variants (markers) assigned to 58 genes,
previously associated with the risk for LC in European decent people or one of its histological subtypes
through a wide variety of approaches [4–11] or proxies
thereof (called LC-marker), and 296 markers assigned
to 7 genes involved in Wnt signalling and listed in Bahl
et al. [25, 26] and Yilmaz et al. [27] (called AhR/Wntmarker). Thus, we focused this analysis to genes previously investigated with respect to LC. Fifty of these
409 markers were eliminated before analysis due to a
MAF < 1% (minor allele frequency), or departure from
HWE (Hardy–Weinberg equilibrium) in genotypes
(unaffected p < 10–7, affected p < 10–12), or low imputation accuracy (info < 0.8). Seventy-eight of the remaining LC-markers were genotyped with the OncoArray
(44 thereof are proxy SNPs identified using LDlink [29])
and 32 had to be imputed. Two hundred and twenty
one of the remaining AhR/Wnt-markers were genotyped and 28 have been imputed. A list of these markers extracted from ILCCO OncoArray repository is
given in the Additional file 1.
Association analysis

We first performed association analysis for each marker
separately using the program PLINK [30, 31]. Crude
(model 1) and adjusted odds ratios (ORs) were estimated along with 95%-confidence intervals within logadditive models. Sex, age and smoking status and the
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first 3 principal components (PCs) to adjust for population stratification (model 2); and in addition the 6
most significantly associated LC-markers (rs55781567,
15q25.1 CHRNA5; rs11780471, 8p21.2 CHRNA2;
rs7705526, 5p15.33 TERT; rs56113850, 19q13.2
CYP2A6; rs71658797, 1p31.1 AK5; rs11571833, 13q13.1
BRCA2) (model 3) were included in adjusted models. ORs were estimated for overall LC, small cell LC
(SCLC), squamous cell LC (SqCLC), adenocarcinoma
LC (adenoLC), ever smokers, never smokers and individuals aged ≤ 55 years (early onset LC) as subgroups.
We generated QQ-plots for the AhR/Wnt-markers and
estimated the genomic inflation factor λ. To account for
multiple testing, genome-wide statistical significance
was considered to correspond to a p value of 1
 0−7 or
lower, suggestive significance to a p value between 1
 0−5
−7
and 10 and nominal significance to a p value between
0.05 and 1
 0−5.
Logistic regression—predicting models with model
selection

We fitted logistic regression models with variable selection to find appropriate polygenic risk scores (PRS)
to predict the disease (LC) status (affected or unaffected). Any AhR/Wnt-marker or the LC-marker could
be included in the model without preference. To avoid
multi-collinearity we removed one of two SNPs in LD
to another (R2 > 0.8, pruning). The remaining entered
the models as potential predictors. We performed forward selection until the Bayesian information criterion
(BIC, most stringent selection), the Akaike information criterion (AIC, less stringent selection, contains in
general more predictors) or the sample size corrected
AIC (AICC) indicate a best solution (and 10 more selection steps). The resulting PRSs are called BIC-, AIC- and
AICC-scores. Note, that for the purpose of model building, the AIC-selection is asymptotically equivalent to
cross-validation (CV) [32, 33]. To avoid overfitting, we
assigned individuals to a training or a validation set (to
build a score) and a testing set (to examine the score
performance) with a 1/3 probability each. For comparison, we also generated a BICLC-score with at least one
marker, only allowing LC-markers to enter the model
building. To compare the importance for LC prediction
of the sets g of LC-makers and AhR/Wnt-markers, respectively,we contrasted the importance-values defined as
Ig = m∃g |βm | • MAFm for each score (MAFm the minor
allele frequency and βm the logistic regression coefficient
of marker m). The superiority of the AIC-scores over
the BICLC-score and the BIC-score was tested applying
the nonparametric test of DeLong et al. [34] (1-sided)
on AUCs of ROC (area under the receiver operation
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characteristic curve). In addition, a corresponding precision-recall plot was created for the SCLC.
Decision trees

Decision trees were created to examine marker × marker
interaction with respect to the LC prediction. Any
AhR/Wnt-marker or the LC-marker could be included
in a tree without preference. This was accomplished in
the entire sample and in all subgroups defined above.
The R packages rpart and DescTools were used [35, 36].
To avoid trees being formed by spurious epistasis we
removed one of two SNPs in LD to another (R2 > 0.8,
pruning). Since overfitting is a point of concern when
building decision trees, the complexity parameter was
first optimized applying ten-fold cross-validation, grading the performance on the validation set by Somers’ D
(concordance of true and predicted LC-status). The ability of the optimal trees to predict the LC-status was then
tested within the independent sample of 4359 cases and
controls. True positive (TP) and true negative (TN) rates
are given.
All statistical analyses were performed with S
 AS® 9.4,
PLINK 1.90 and 2.0 or R 4.0.2.
Gene expression

We extracted information on gene expression from the
Human Protein Atlas [37, 38] and LungGENS [39, 40].
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Results
Sample description

The analysed sample consists of 14,068 LC-cases and
12,390 controls with median age of 63. Sixty-three percent were male, 52% of cases and 28% of controls were
current smokers. The most frequent histological subtype
is adenocarcinoma (38%), followed by squamous cell carcinoma (SqCLC) (26%) and small cell lung cancer (SCLC)
(10%). The proportion of never-smokers was largest
within the subgroup of adenocarcinoma cases (14%), but
almost the same between those cases aged ≤ 55 years
(10%) and aged > 55 years (9%). Details on smoking status and histological subtypes are presented in Table 1.
Association analysis

We first performed association analysis for each
Wnt/AhR-marker separately. The p values for an association of AhR/Wnt-markers with LC range from 0.005
(rs12115174; 8p11.21 DKK4; OR = 0.9211) to 1 (model
2; adjusted for sex, age, smoking status and population stratification); with a negligible genomic inflation
(λ = 1.02). A nominally significant association (10–5 <
p ≤ 0.05) was observed for only 8 of the 249 markers
(~ 3%). The corresponding point estimates of OR range
from 0.88 (rs1053070054; 8p11.21 DKK4; p = 0.007) to
1.12 (rs74596148; 7p14.1 SFRP4; p = 0.25). A QQ-plot
indicates that achieved p values almost perfectly agree
with the expectation of no associated marker (see Fig. 1).
p values and OR are in moderate agreement between the

Table 1 Smoking by LC status and subgroups
Never smoker

Ever smoker

Total

Never

Former

n

n

%

n

Evera

Current
%

n

%

n

%

Control
Age ≤ 55 years

Age > 55 years
All

2762

951

34

698

25

896

32

217

8

9628

2960

31

3572

37

2568

27

528

5

12,390

3911

32

4270

34

3464

28

745

6

Case
SqCLC

3692

138

4

1257

34

2158

58

139

4

SCLC

1450

48

3

383

26

965

67

54

4

Other LC

3629

405

11

1200

33

1820

50

204

6

AdenoLC

5297

740

14

1989

38

2401

45

167

3

281

10

452

16

1945

70

87

3

1050

9

4377

39

5399

48

477

4

Age ≤ 55 years

Age > 55 years

2765
11,303

All

14,068

1331

9

4829

34

7344

52

564

4

Total

26,458

5242

20

9099

34

10,808

41

1309

5

SCLC small cell lung cancer; SqCLC squamous cell lung cancer; AdenoLC adenocarcinoma of the lung; other LC other histological subtypes
a

As recorded
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Fig. 1 Association of AhR/Wnt-marker. Left panel: QQ-Plot for model 2 (adjusted for sex, age and smoking status and the first three principal
components); right panel: matrix of p values generated by model 1 (crude), model 2 (adjusted for sex, age and smoking status and the first three
principal components) and model 3 (additionally adjusted for 6 selected LC-markers), genome-wide significance: p value ≤ 10−7, suggestive
significance: 10−7 < p value ≤ 10−5, nominal significance: 10−5 < p value ≤ 0.05

models (e.g., model 2–3; additionally adjusted by LCmarkers: Kendall’s rhop = 0.75, rhoOR = 0.78).
Subgroup analysis

When dividing the cases according to histological subtypes (SCLC; SqCLC and adenoLC) the observation of no
detectable association for WNT/AhR-markers remains.
Merely the number of nominally significant association
(10–5 < p ≤ 0.05) increases to 12 (5%) or 21 (8%) of the
249 markers for SqCLC and SCLC, respectively, hence
close to the expected type 1 error. (Additional file 1:
Table S2). When dividing the cases and controls according to their smoking behaviour (ever and never smokers),
genome-wide significance (p ≤ 10–7) was achieved for 7
and 8 markers, respectively. Another 12 and 3 markers,
respectively, were found suggestively significant 
(10–7
–5
< p ≤ 10 ) (see Additional file 1: Figure S1) for ever and
never smokers. Those markers found associated among
ever smokers have mainly been directly genotyped
and are assigned to SFRP4 and DKK4. For example, for
marker rs2722278 we estimated an OR = 1.20 (95% CI
1.13–1.27), yielding a p value of 5.6 × 10–10. Those markers found associated among never smokers have mainly
been imputed and are mostly assigned to Axin2, but also
to AHR, FRZB and DKK2. Marker rs17037102, assigned
to DKK2, was the only one found associated with LC by
Bahl et al. and in this analysis (see Table 2 and Additional
file 1: Table S3). Interestingly, the ORs of these markers
estimated by model 3 (additionally adjusted for selected
LC-marker) differ from that estimated by model 2. They

are closer to one and no more significant. For example,
for rs1133683 (Axin2) we observe an OR = 1.27 (95% CI
1.19–1.35, p = 1 × 10–12) fitting model 2, but OR = 0.95
(95% CI 0.86–1.06, p = 0.3586) fitting model 3.
Logistic regression—predicting models with model
selection

We further fit logistic regression models with variable
selection to evaluate the contribution of AhR/Wnt-markers to a polygenic risk scores (PRS), but without postulating the usefulness of the score as such. Eight LC-markers
from only eight LC-genes (CYP2A6, CHRNA5, TERT,
AMICA1, CHRNA3, COPS2, HCG4 and CHRNA2)
were selected for the BIC-score (most stringent selection) to predict overall LC. Hence, the BIC-score and
the BICLC-score are identical. In contrast, the AIC-score
(for overall LC identical to the AICC-score) includes 20
LC-markers and remarkable 17 AhR/Wnt-markers, with
LC-markers being more important than the AhR/Wntmarkers (importance ratio 0.56: 0.34) (see Fig. 2, Additional file 1: Figure S3 and Table S4). The ability to
distinguish cases and controls from susceptibility genes
only was, as expected, poor for each of the scores (see
Additional file 1: Table S5). In the training set the performance of the AIC/AICC-score (AUC = 0.607) exceeded
those of the BIC/BICLC-score (AUC = 0.582) significantly
(p < 0.001). Within the test set (AUCs: 0.577 and 0.576)
and the 2nd validation set (AUCs: 0.553 and 0.548), the
higher complexity with additional AhR/Wnt-markers did
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Table 2 Significantly associated AhR/Wnt-markers within never and ever smokers
SNP

Cyto band

MAF (%)

Gene

Model 2

Model 1

Model 3

p value

OR

95% CI

OR

OR

3.4 × 10–13

0.72

0.66–0.79

0.71

0.90 ns

9.9 × 10–14

0.71

0.65–0.78

0.71

0.90 ns

1.0 × 10–12

1.27

1.19–1.35

1.27

0.95 ns

5

7.7 × 10–24

0.41

0.34–0.49

0.40

0.62 ns

9

3.2 × 10–22

0.58

0.52–0.65

0.58

1.10 ns

9

3.7 × 10–19

0.62

0.56–0.69

0.62

1.10 ns

Never smoker
Imputed
  rs202198518a

7p21.1

14

AHR

Imputed
  rs2237297a

14

Imputed
  rs1133683

17q24.1

42

Axin2

Imputed
  rs2240307
Imputed
  rs35285779a
Imputed
  rs35415678a
Imputed
  rs288326

2q32.1

10

FRZB

2.5 × 10–8

1.42

1.25–1.60

1.41

0.98 ns

4q25

15

DKK2

7.4 × 10–15

0.69

0.63–0.76

0.69

1.09 ns

7p14.1

45

SFRP4

1.3 × 10–9

1.14

1.09–1.19

1.15

1.13ss

36

1.3 × 10–8

0.88

0.84–0.92

0.88

0.88gws

42

1.8 × 10–8

0.88

0.85–0.92

0.89

0.89gws

42

1.6 × 10–8

0.88

0.85–0.92

0.89

0.89gws

16

5.6 × 10–10

1.20

1.13–1.27

1.16

1.20gws

11

9.0 × 10–9

1.22

1.14–1.31

1.17

1.23gws

43

7.9 × 10–8

0.89

0.85–0.93

0.89

0.89gws

9.4 × 10–11

1.20

1.14–1.27

1.15

1.08ss

Imputed
  rs17037102
Ever smoker
Genotyped
  rs12532321
Genotyped
  rs7811872
Genotyped
  rs10226308
Genotyped
  rs10488617
Genotyped
  rs2722278
Genotyped
  rs2722279
Genotyped
  rs7811420
Imputed
  rs2073664

8p11.21

9

DKK4

Model 1: crude odds ratio (OR); model 2: adjusted for sex, age and smoking status and the first three principal components; model 3: OR additional adjusted for 6
selected LC-markers. Only markers are listed for which genome-wide significance (p value ≤ 10–7) was achieved
MAF minor allele frequency; gws genome-wide significant (p value ≤ 10−7); ss suggestive significant (10−7 < p value ≤ 10−5); ns not significant (p > 0.05)

a

Pair of markers in LD (R2 > 0.8 in populations of European decent)

not improve discriminability for overall LC (p = 0.87 and
p = 0.35).
Similar score composition and performance was
observed for most subgroups. The BIC-scores in the subgroups adenoLC (involved marker LC:AhR/Wnt = 6:–),
SCLC (3:–) and smokers (7:–) contained LC-markers
only, whereas AhR/Wnt-markers are included even
under this stringent variable selection in the subgroups
SqCLC (5:1) and Early onset LC (2:2). However, between

14 and 31 AhR/Wnt-markers entered these subgroup’s
AIC-scores. For these subgroups, the importance of the
LC-markers for the AIC-score is higher than that of the
included AhR/Wnt-markers.
Most important, we observed a significantly higher
predictive accuracy (larger AUCs) of the AhR/Wnt-markers enriched AIC-scores compared to B
 ICLC–score in the
subgroup of SCLC patients (p = 0.019; AUCAIC = 0.577
AUCBIC = 0.546) within the test set (see Additional file 1:
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Fig. 2 Comparison of score composition. LC lung cancer; AIC score score of a logistic regression model with variant selection according to the
Akaike information criterion (AIC); MAFm minor allele frequency of variant (marker) m; βm regression parameter of variant m; LC-associated genes
previously reported as associated to LC or one of its histological subtypes; AhR/Wnt-genes selected genes assigned to Wnt-signalling, including
AhR; Smoker ever, former and current smoker; SCLC small cell lung cancer, SqCLC squamous cell lung cancer, Early onset LC: aged ≤ 55 years; TERT is
framed in orange, because telomerase activity is related to Wnt signalling

Fig. 3 ROC and precision-recall-plot: SCLC. The diagnostic performance of the AIC-score compared to the BIC/BICLC-score in the test-set is
presented. Left panel: ROC receiver operation characteristics; right panel: corresponding precision-recall plot; precision = (true positive cases)/(true
positive cases + false positive controls), positive predictive value (PPV) = (sensitivity × pre-test-probability)/[(sensitivity × pre-test-probability) +
(1 − specificity × 1 − pre-test-probability)] for a pre-test-probability of 5%
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Figure S4). For this subgroup, the selected AhR/Wntmarkers contribute to the AIC-score more than twice
as much as the LC-markers (importance ratio 0.60:1.49).
The precision-recall plot of Fig. 3 indicates that a positive
SCLC prediction based on the AIC-score can be trusted
more than that based on LC-markers alone (BICLC-score).
In the 2nd validation set the score-specific AUCs were
similar but no more significantly different (p = 0.08; AUC
AIC = 0.564 vs. AUC
BIC = 0.531). The AIC-score of this
SCLC-subgroup is composed of 12 LC-markers (assigned
to CHRNA5, HCG4, DNAJB4 (4 × each), CYP2A6,
CHRNA3, CHRNA2, AMICA1, KCNJ4, AS1, BRCA2,
EGFL8 and WNK1 (2 × each) and 27 AhR/Wnt-markers
(assigned to all AhR/Wnt-genes except DKK3). However,
only one LC patient in the test set (n = 434) and one
in the 2nd validation set (n = 164) was recognized as a
patient at a threshold of 50% case probability.
Interestingly the BIC-score for never smokers was
built by only two AhR/Wnt-markers (assigned to Axin2
and SFRP4) but not a single LC-marker. Furthermore,
the LC-markers are the minority in the composite of the
AIC-score (15:23). They also contribute less to the AICscore than the AhR/Wnt-markers (importance ratio of
0.96:1.46). The median predicted case probability, in the
test set (24.8%) and 2nd validation set (25.6%), exceeds
that of controls by 1–2%-points. However, AUC differed
neither in the test set (p = 0.13; AUCAIC = 0.540 AUCBIC
= 0.514) nor in the 2nd validation set (p = 0.36; AUCAIC
= 0.535 AUCBIC = 0.526) significantly. Nevertheless, this
observation highlights the value of the AhR/Wnt-markers
in the subgroup of never smokers.

Remarkably, a marker assigned to CHRNA5 was always
chosen as the first and most important split for the trees
for ever smokers, for SCC and SqCLC. However, markers assigned to AhR/Wnt-genes (smoker: DKK2; SCLC:
FRZB; SqCLC; DKK2 and DKK3) appear at lower-level
decision-nodes (Additional file 1: Figures S5–S8). With
the same program settings, no decision tree could be created for adenocarcinoma.
Most notable is the optimal decision tree for the 5242
never smokers (75% LC-cases, 25% controls), the only
one that does not contain a marker belonging to the
CHRN (Cholinergic receptors nicotinic subunits) gene
group (see Fig. 4). The tree is built from only two LCmarkers but 7 AhR/Wnt-markers, achieving a Somers’
concordance index D = − 0.002. One can make out three
branches of this tree. Branch I covers two thirds of individuals (n = 754, 66% of 1141 in the 2nd validation set):
all of these are graded as “unaffected” based on only the
two LC-markers: first decision node (rs885518 assigned
to MTAP) and second decision node (rs7705526 assigned
to TERT that links telomerase activity to Wnt signalling).
For branch II an additional node (rs17214897 assigned
to DKK2) is taken into account, covering a further tenth
(9.9%) of never smokers. In this branch, very few subjects of the training set (1.7% within branch II eq. 0.17%
of all never smokers) are graded “affected”. However,
one in four individuals of the 2nd validation set belonging to both branches, I and II, is truly “affected” but has
not been detected (TP-rate = 0%, TN-rate = 100%).
Rated as “affected” appears in the test set only in the third
branch III, covering the remaining fourth of never smokers (n = 284 of the 2nd validation set). This third branch
requires genotypes of several AhR/Wnt-markers assigned
to AHR, Axin2, DKK2 and/or SFRP4. Herein, one in
three (n = 97 of the 2nd validation set) is truly “affected”
and is given a chance to be correctly identified, which
appears in 8 LC-cases (TP-rate = 9%, TN-rate = 88%).
We also noted that the histological subtypes are equally
distributed between the branches (see Additional file 1:
Table S7).

Decision trees

Finally, we generated decision trees to evaluate the contribution of AhR/Wnt-markers to LC prediction that
allow for a complex interaction structure, but without postulating the usefulness of the trees as such. The
decision tree for overall LC (whole sample) consists off
solely a single decision node (rs55781567 assigned to
CHRNA5), achieving a Somers’ concordance index D
= 0.0565 in the 2nd validation set (see Additional file 1:
Table S6 and Figure S2). A single-node decision-tree
was also found optimal for participants aged ≤ 55 years
(split: rs1051730 assigned to CHRNA3), achieving a Somers’ concordance index D = 0.096. These two, unsophisticated trees are characterised by balanced TP- (about
62%) and TN-rates (about 44%).
The decision trees for ever smokers, SCLC and SqCLC
were more complex achieving Somers’ concordance
indexes D of 0.007, − 0.0005 and 0.0126, respectively.
The trees for SCLC and SqCLC are characterised by an
extreme TP-rate < 5% and TN-rate > 99%; the tree for
Ever Smokers by a TP-rate > 99% and TN-rate < 5%.

Gene expression

AHR, Axin2, DKK3 are ubiquitously expressed, with
RNA expression detected in many tissues and evidence
for protein expression. Axin2 and DKK3 are moderately
to highly expressed in normal lung tissues according to
the Human Protein Atlas [37]. AhR is expressed at low
levels in macrophage cells of the lung. No expression is
reported for other Wnt/AhR-genes (see Additional file 1:
Figure S9 and Table S9). Significant differential expression is listed in LungGENS for AhR, Axin2 DKK2, DKK3
and SFRP4 [39] (see Additional file 1: Table S8). Furthermore, AhR is reported to be abundantly expressed in
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Fig. 4 Decision tree for never smoker. Node information: gene name, marker; split information below the node: threshold for minor allele count;
blue split nodes: LC-genes, orange split nodes: AhR/Wnt-genes,; TERT is framed in orange, because telomerase activity is related to Wnt signalling;
decision nodes and bars: green for unaffected; red for affected, TN true negative rate, TP true positive red; the size of gene names, lines and decision
notes is proportional to the size of the respective (sub)sample

solid lung tumours, especially in adenocarcinomas. AhR
overexpression was associated with upregulation of IL-6
secretion, which is critical for lung cancer initiation [41].
Detailed information on gene expression is given in the
Additional file 1. In addition, the DKK1 serum level was
seen as significantly lower in NSCLC and SCLC patients
compared to healthy controls [42]. Significant upregulation of DKK2 expression was found in APC (adenomatous polyposis coli)-mutated non-SCLC lung cancers
[43].

Discussion
This investigation was intended to discover association
of the Wnt-genes DKK4 (8p11.21), DKK3 (11p15.3),
DKK2 (4q25), FRZB (2q32.1, also known as sFRP3),
SFRP4 (7p14.1), Axin2 (17q24.1) and a potential interaction with AhR-genes, to LC in a large sample of 26,458
individuals of European descent. No marginal association of AhR/Wnt-markers with overall LC was observed.
Interestingly, an accumulation of associated markers
was observed splitting the sample by smoking status,
where respective markers in ever smokers are assigned
to SFRP4. On the other hand, association analysis in
never smokers reflects complex gene–gene interactions,

as markers of several AhR/Wnt-genes were found to be
genome-wide associated with LC. This complexity is also
visible through the decision tree analysis.
Our results are in line with findings from northern
India [25, 26] and from Istanbul, Turkey [27], both of
which are based on much smaller samples (approx. 600
and 270 people, respectively). In these investigations, the
interaction of DKK2 and DKK3 with SFRP4 and Axin2
polymorphisms turned out to be the best (of all examined) predictors of LC, especially in smokers. Axin2, but
also AHR, FRZB and DKK2, were observed to be complex associated in never smokers. Our analysis agrees
with both previous studies that complex interaction patterns between the examined genes contribute to overall
LC susceptibility or within certain subgroups. However,
we have not been able to replicate reported single marker
associations directly.
To discover patterns of AhR/Wnt-genes involved in LC
genesis we further changed the focus from significance
of association to inclusion in prediction models, and followed two approaches: first, we searched for polygenic
risk scores (PRS). Doing so, we add up marker main
effects to construct multidimensional scores, optimising model fit (instead of marker preselection by p-value
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below some threshold), to discriminate cases from controls in a somehow ideal way. Complex gene × gene
(G × G) interactions are not modelled.
Nevertheless, the proportion of AhR/Wnt-genes entering some of the predictive models was remarkable
large, given that these markers are not, all other candidates, however, genome-wide significantly associated
to LC. This was particularly noticeable for SCLC, since
AhR/Wnt-markers contribute more than twice as much
to the prediction score as LC-markers. It is known, that
within current smokers, tobacco consumption is strongest associated to SCLC [44]. Moreover, within never
smokers, a stringed defined score is made up from only
two AhR/Wnt-markers, assigned to Axin2 and SFRP4.
However, the discriminative ability of PRSs for LC, contributing markers with significance for main effect at different levels, is in general poor. The AUC of the B
 ICLC
score for overall LC (0.58 in the test set and 0.55 in the
2nd validation set) corresponds to the AUC = 0.54 based
on four top LC-genes in a simulated population, as given
by the GWAS-ROCS Database (https://gwasrocs.ca/).
This may be due to other overpowering risk factors, since
models including, e.g., age, sex and smoking variables
achieve higher AUCs (0.62–0.79) [45].
Recently two polygenic risk scores (PRSs) for overall-LC
had been developed, validated and assessed with respect
to improving eligibility to low-dose computed tomography (LDCT) as the only recommended screening test for
lung cancer. Jia et al. [46, 47] build a PRS on 19 genomewide associated SNPs (p < 0.5 × 10–8). Hung et al. [48],
integrated their PRS on 128 SNPs (35 “known” LC-related
loci, 93 suggestive associated loci selected by LASSOregression model) into the P
 LCOall2014 risk model. Both
approaches have been validated using data from the UK
Biobank. For both scores, the mean PRS differed only
slightly between LC cases and cancer-free controls (Jia:
effect size ~ 0.19; Hung: effect size ~ 0.22). For both
scores, no substantial increase in discriminability of cases
from controls is reported, when adding the PRS to existing risk models (Jia: family history—AUC = 0.589, family
history + PRS – AUC = 0.615; Hung: P
 LCOall2014–AUC
= 0.828, PLCOall2014 + PRS – AUC = 0.832). However,
both were able to show that the age at which a smoker
crosses the recommended screening threshold of 1.5% for
the 5-year LC risk depends on the genetic background,
which is sufficiently quantified by the PRS examined.
Some smokers will be eligible by < 50 years of age, others by > 60 years of age. Hence, constructing reliable PRS,
even with small discriminability, may help to improve the
performance of LDCT.
Two- and multiway G × G interaction can also contribute to LC susceptibility, rather than just markers with
observed (marginal) main effects. G × G interaction is
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in general less commonly investigated, not only because
this requires much larger samples. However, Li et al.
[49] found RGL1:RAD51B in overall LC and non-SCLC,
SYNE1:RNF43 in adenocarcinoma and FHIT:TSPAN8
in SqCLC to interactively contribute to LC susceptibility. As in the presented data analysis, the impact of these
genes would also have been overlooked considering main
effects only. Another reason could be that LC itself is
just a generic term of several subcategories that differ in
terms of LC initiation and require separate PRSs [45, 50].
A third reason of the poor performance may be due to
the exclusively concentration on genetic effects, rather
than modelling lifelong interaction with the environment
as well. For example, G × E interaction effects for LC
have been observed smoking [51], exposure to asbestos
fibres [52, 53] and exposure to radon [54, 55].
With this in mind, the data analysis presented shows
that the complex interaction of Wnt-related genes has the
potential to be part of an adequate risk assessment for
never-smokers or in relation to certain histological subtypes of LC.
As a second approach, we constructed decision
trees, which mainly depict G × G interaction patterns.
Although, the ability to discriminate cases from controls
is again poor, CHRNA5 was in general the most important first node for overall LC and in many subgroups.
AhR/Wnt-genes play a complex but important role in
at least one quarter of never smokers, as seen before.
Remarkably, TERT, which links telomerase activity to
Wnt signalling, was central in that branch and important
for the remaining three quarters of never smoker. This
corresponds to a concentration of relevant genes for this
subgroup in the CLPTM1L-TERT region on chromosome
5, as previously reported by Hung et al. [56]. Our observations confirm the suspicion, that LC in never smokers
is a different entity, justified beforehand on differences
in epidemiological, clinical and molecular characteristics
[50].
We would like to emphasize that this study was not
intended to provide a definitive and reliable risk assessment, but rather aimed to examine in depth the LCrelevant complex interaction pattern of AhR/Wnt-genes
hypnotized by Bahl et al. Indeed, considering prediction
instead of association provides weaker evidence for this,
but is valid in view of the large amount of external evidence. The importance of the Wnt-signalling pathway
and its antagonist’s sFRP, DKKs and Axin2 for cancer is
outlined in the introduction. One can also assume a connection with the molecular functionality, since involved
genes are expressed ubiquitously or in lung tissues.
Although the large-scale, thoroughly quality checked,
and representative sample of genetically proven European
descent individuals was used for the presented analysis,

Rosenberger et al. European Journal of Medical Research

(2022) 27:14

some limitations must be noted. We used a rather narrow definition of AhR/Wnt-genes to limit the number of
possible interactions. An extension to, e.g., EGRF, APC,
FRAT2 or the CYP-family would also be justified. We
further could have chosen the random forest method as
a more contemporary and robust approach than decision
trees, but we would not be able to present our results so
illustrative. However, the sample size allowed subgroup
analyses, whereby the special importance of AhR/Wntgenes for SCLC and never smokers could be shown.

Conclusions
The role of markers belonging to Wnt signalling and the
AhR pathway in LC susceptibility may be underrated in
main-effects association analysis. Complex interaction
patterns in individuals of European decent have moderate predictive capacity for LC or subsets thereof, especially in never smokers.
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